ASN-RASAGILINE TABLET

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

RASAGILINE (RASAGILINE MESYLATE)

थमां उपलब्ध:

ASCEND LABORATORIES LTD

ए.टी.सी कोड:

N04BD02

INN (इंटरनेशनल नाम):

RASAGILINE

डोज़:

0.5MG

फार्मास्यूटिकल फॉर्म:

TABLET

रचना:

RASAGILINE (RASAGILINE MESYLATE) 0.5MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

100

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

MONOAMINE OXIDASE B INHIBITORS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0151662001; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2019-06-04

उत्पाद विशेषताएं

                                PRODUCT MONOGRAPH
Pr
ASN-RASAGILINE
RASAGILINE MESYLATE
0.5 MG AND 1 MG RASAGILINE TABLETS (AS RASAGILINE MESYLATE)
ANTIPARKINSON AGENT
Ascend Laboratories Ltd.
35 Nixon Road, Unit 10
Caledon, Ontario
L7E 1K1
Date of Preparation:
May 30, 2019
Control Number: 221339
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
CLINICAL TRIALS
..........................................................................................................23
DETAILED PHARMACOLOGY
.....................................................................................28
T
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 03-05-2019

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें